1. Catalog
  2. Palliative Care and Advanced Liver Disease
Palliative Care and Advanced Liver Disease
Image For Activity Cover
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $200.00
Patient: $0.00
Associate: $120.00
Student: $0.00
Early Career: $120.00
Industry Rep: $200.00
Credit Offered
2 AMA PRA Category 1 Credits
2 ABIM MOC Points
2 Attendance Credits
2 Participation Credits
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Recommended
Patients with decompensated cirrhosis struggle with significant physical and psychological symptoms, resulting in poor health related quality of life. The only curative treatment is liver transplantation, which is not a viable option for most who suffer from cirrhosis. Palliative care (PC), an approach that improves the quality of life of patients and their families through the prevention and relief of suffering (WHO), is becoming increasingly recognized as an important care model to provide alongside standard medical treatment for patients with decompensated cirrhosis.

Recent survey studies have shown that most hepatologists support early PC intervention for patients with end stage liver disease (Ufere) and many desire more education on management of physical and psychological symptoms (Whitsett). As such, a recent AASLD Guidance was published supporting early integration of PC for all patients with advanced liver disease and summarizing approaches to communication and complex symptom management (Rogal).

The purpose of this AASLD LiverLearning program is to provide clinically applicable, high yield education regarding the most important facets of PC for patients with decompensated cirrhosis. Authors of each module represent highly published experts in the field from multiple disciplines, including gastroenterology, transplant hepatology, nursing, oncology, and palliative care.
Upon completion of this course, participants should be able to:

  • Define palliative care and understand differences between palliative care and hospice
  • Communicate more effectively with patients and caregivers about symptoms, distress, and goals of care
  • Provide treatment options for debilitating physical and psychological symptoms of decompensated cirrhosis
Accreditation Statement

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The American Association for the Study of Liver Diseases designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Credits

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board.

As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education. The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Alyson Kaplan, MD, MS
Nothing to Disclose

Amy Johnson, DO, MBBS, BSc
Nothing to Disclose

Arpan Patel, MD, PhD
Nothing to Disclose

Brittany Waterman, MD
Nothing to Disclose

Christopher Woodrell, MD
Grant/Research Support:  American Cancer Society, National Institutes of Health

Claudio Tombossi, MD
Nothing to Disclose

Cristal Brown, MD
Nothing to Disclose

David Harris, MD
Nothing to Disclose

Janice Jou, MD, MHS, FAASLD
Grant/Research Support: Gilead

Kamron Pourmand, MD
Nothing to Disclose

Lissi Hansen, PhD
Grant/Research Support: National Institutes of Health

Manisha Verma, MD, MPH
Nothing to Disclose

Mina O. Rakoski, MD, FAASLD
Scientific Consultant/Advisor: Mallinkrodt
Speakers Bureau: Gilead

Peter Beah, MD
Nothing to Disclose

Seren M. Gedallovich, MD
Nothing to Disclose

Staff:

Manuel Calderon, M.Ed., CPTD
Nothing to Disclose

Wendy Risso, MPH
Nothing to Disclose

Laura Shelters, MS Ed.
Nothing to Disclose
Powered By